Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody

References

• Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C, Türeci Ö. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008 Dec 1;14(23):7624–9. doi:10.1158/1078-0432.CCR-08-1547.
   PubMed Web of Science ®Google Scholar
• Türeci Ö, Koslowski M, Helftenbein G, Castle J, Rohde C, Dhaene K, Seitz G, Sahin U. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 2011 Aug 1;481(2):83–92. doi:10.1016/j.gene.2011.04.007.
   PubMed Web of Science ®Google Scholar
• Coati I, Lotz G, Fanelli GN, Brignola S, Lanza C, Cappellesso R, Pellino A, Pucciarelli S, Spolverato G, Guzzardo V, et al. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. Br J Cancer. 2019 Jul;121(3):257–263. doi:10.1038/s41416-019-0508-4.
   PubMed Web of Science ®Google Scholar
• Karanjawala ZE, Illei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, Schulick R, Winter J, Sharma R, Maitra A, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol. 2008 Feb;32(2):188–196. doi:10.1097/PAS.0b013e31815701f3.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S, Kokudo N, Fukayama M. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem. 2011 Oct;59(10):942–952. doi:10.1369/0022155411420569.
   PubMed Web of Science ®Google Scholar
• Wöll S, Schlitter AM, Dhaene K, Roller M, Esposito I, Sahin U, Türeci O. Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731–739. doi:10.1002/ijc.28400.
   PubMed Web of Science ®Google Scholar
• Shinozaki A, Shibahara J, Noda N, Tanaka M, Aoki T, Kokudo N, Fukayama M. Claudin-18 in biliary neoplasms. Its significance in the classification of intrahepatic cholangiocarcinoma. Virchows Arch. 2011 Jul;459(1):73–80. doi:10.1007/s00428-011-1092-z.
   PubMed Web of Science ®Google Scholar
• Micke P, Mattsson JS, Edlund K, Lohr M, Jirstrom K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Ponten F, et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer. 2014 Nov 1;135(9):2206–2214. doi:10.1002/ijc.28857.
   PubMed Web of Science ®Google Scholar
• Tureci Ӧ, Mitnacht-Kraus R, Woll S, Yamada T, Sahin U. Characterization of zolbetuximab in pancreatic cancer models. Oncoimmunology. 2019;8(1):e1523096. doi:10.1080/2162402X.2018.1523096.
   PubMed Web of Science ®Google Scholar
• Lordick F, Thuss-Patience P, Bitzer M, Maurus D, Sahin U, Türeci Ö. Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer. J Cancer Res Clin Oncol. 2023 Jan 6;149(9):5937–5950. doi:10.1007/s00432-022-04459-3.
   PubMed Web of Science ®Google Scholar
• Sahin U, Schuler M, Richly H, Bauer S, Krilova A, Dechow T, Jerling M, Utsch M, Rohde C, Dhaene K, et al. A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. European J Cancer. 2018 Sep;100:17–26. doi:10.1016/j.ejca.2018.05.007.
   PubMed Web of Science ®Google Scholar
• Türeci Ö, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 Sep 1;30(9):1487–1495. doi:10.1093/annonc/mdz199.
   PubMed Web of Science ®Google Scholar
• Sahin U, Tureci O, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, Dudov A, Bazin I, Bondarenko I, Melichar B, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609–619. doi:10.1016/j.annonc.2021.02.005.
   PubMed Web of Science ®Google Scholar
• Lordick F, Al-Batran SE, Ganguli A, Morlock R, Sahin U, Türeci Ö. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma. Gastric Cancer. 2021 May;24(3):721–730. doi:10.1007/s10120-020-01153-6.
   PubMed Web of Science ®Google Scholar
• Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023 Apr 14;401(10389):1655–1668. doi:10.1016/S0140-6736(23)00620-7.
   PubMed Web of Science ®Google Scholar
• Xu R-H, Shitara K, Ajani JA, Bang Y-J, Enzinger PC, Ilson DH, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, et al. Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2− locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: primary phase 3 results from GLOW. J Clin Oncol. 2023;41(36_suppl):405736–405736. doi:10.1200/JCO.2023.41.36_suppl.405736.
   Google Scholar
• Stadler CR, Bahr-Mahmud H, Celik L, Hebich B, Roth AS, Roth RP, Kariko K, Tureci O, Sahin U. Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nat Med. 2017 Jul;23(7):815–817. doi:10.1038/nm.4356.
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci Ö, Brandenburg G, Usener D, inventors. Monoclonal antibodies against claudin-18 for treatment of cancer. United States patent US8425902B2. 2013.
   Google Scholar
• Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Tureci O, Sahin U. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006 Dec 15;108(13):4009–4017. doi:10.1182/blood-2006-04-015024.
   PubMed Web of Science ®Google Scholar
• Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, Diken M, Lower M, Vallazza B, Beissert T, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3’ UTRs identified by cellular library screening. Mol Ther. 2019 Apr 10;27(4):824–836. doi:10.1016/j.ymthe.2018.12.011.
   PubMed Web of Science ®Google Scholar
• Rybakova Y, Kowalski PS, Huang Y, Gonzalez JT, Heartlein MW, DeRosa F, Delcassian D, Anderson DG. mRNA delivery for therapeutic anti-HER2 antibody expression in vivo. Mol Ther. 2019 Aug 7;27(8):1415–1423. doi:10.1016/j.ymthe.2019.05.012.
   PubMed Web of Science ®Google Scholar
• Wu L, Wang W, Tian J, Qi C, Cai Z, Yan W, Xuan S, Shang A. Intravenous delivery of RNA encoding anti-PD-1 human monoclonal antibody for treating intestinal cancer. J Cancer. 2022;13(2):579–588. doi:10.7150/jca.63991.
   PubMed Web of Science ®Google Scholar
• Hashimoto I, Oshima T. Claudins and gastric cancer: an overview. Cancers. 2022;14(2):290. doi:10.3390/cancers14020290.
   PubMed Web of Science ®Google Scholar
• Kwaa Abena KR, Talana CAG, Blankson JN, Silvestri G. Interferon alpha enhances NK cell function and the Suppressive capacity of HIV-Specific CD8+ T cells. J Virol. 2019;93(3):10.1128/jvi.01541–8. doi:10.1128/jvi.01541/18.
   PubMed Web of Science ®Google Scholar
• Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G, et al. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol. 2019 May 17;4(35):eaaw6647. doi:10.1126/sciimmunol.aaw6647.
   PubMed Web of Science ®Google Scholar
• Pardi N, Secreto AJ, Shan X, Debonera F, Glover J, Yi Y, Muramatsu H, Ni H, Mui BL, Tam YK, et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat Commun. 2017 Mar 2;8(1):14630. doi:10.1038/ncomms14630.
   PubMedGoogle Scholar
• Thran M, Mukherjee J, Ponisch M, Fiedler K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R, et al. Schlake T. mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Mol Med. 2017 Oct;9(10):1434–1447. doi:10.15252/emmm.201707678.
   PubMed Web of Science ®Google Scholar